Bausch+Lomb Results Presentation Deck
2Q23 Revenue Drivers
BAUSCH + LOMB
●
$941M
2Q22
10%
12%
$1,035M
2Q23
2Q23 Reported
Revenue Growth
2Q23 Constant Currency
Revenue Growth ¹
BAUSCH + LOMB
Growth across all three segments
and all major markets
-$18M revenue FX headwinds
.
Vision Care4
●
67%
$646M
■ Consumer
33%
Contact Lens
+12%
Strong growth in key franchises
Lumify® (+23% reported, +23% cc¹)
Eye Vitamins (+11% reported, +12% cc¹)
Artelac® (+24% reported, +24% cc¹)
Daily SiHy (+42% reported)
• Lens portfolio (+1% reported, +4% cc¹),
excluding impact of distribution facility
disruptions (+8% reported, +10% cc¹)
Surgical
.
24%
52% $195M
24%
2 Q 2 3 CONSTANT CURRENCY REVENUE
+7%
• Consumables (+10% reported, +11% cc¹),
driven by surgical packs
■Implantables ■ Equipment
Consumables/Other
Equipment (+10% reported, +10% cc¹),
impacted by Stellaris system supply
• Implantables (-4% reported, -4% cc¹);
premium IOLS (+22% reported, +33% cc¹),
offset by EyeCee One IOL product hold
Supply constraints and higher cost of
inventory resulting in pressure on margins
Pharmaceuticals 3,4
58%
$194M 42%
U.S.
International
GROWTH 1
+16%
Vyzulta® (+25% reported, +25% cc¹),
+26% TRX growth driving performance²
• International Pharma (+17% reported,
+20% cc¹), growth across all major markets
• U.S. Gx (+10% reported), capitalizing on
competitor supply challenges
1. Constant currency. This is a non-GAAP measure or ratio. See Slide 1 and Appendix for further information on non-GAAP measures and ratios.
2. IQVIA NPA monthly. U.S. only.
3. Effective as of the second quarter of 2023, the company changed the name of the segment from "Ophthalmic Pharmaceuticals" to "Pharmaceuticals". Aside from the change in name, there were no other changes to the segment itself as a result.
4. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment
are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the
periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.
8View entire presentation